Celcuity Reports Q1 Loss Beat, Expands Pivotal VIKTORIA-2 Trial for Gedatolisib
CELC has more than doubled off its 52-week low of $9.51 on elevated volume (2.6× avg).
Summary
Celcuity Inc. reported a smaller-than-expected Q1 loss and significantly expanded its Phase 3 VIKTORIA-2 trial, broadening the potential market for its lead drug candidate, gedatolisib.
Key Events · Product Development and Regulatory · CELC
-
Q1 2026 Financial Results Beat Expectations
Celcuity reported a smaller-than-expected Q1 loss, with adjusted EPS of -$0.86 significantly beating consensus estimates. Net cash used in operating activities increased to $55.1 million, with $387.1 million in cash and investments, providing a runway through 2027.
-
Pivotal VIKTORIA-2 Trial Expanded
The Phase 3 VIKTORIA-2 clinical trial was expanded to include a second study (Study 2) evaluating gedatolisib as first-line treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancer, significantly broadening the drug's potential market.
-
Subcutaneous Formulation Development Initiated
Development of a subcutaneous formulation for gedatolisib is underway, with the first patent application submitted. This aims to provide a more convenient injection alternative to infusion, supporting long-term lifecycle development.
-
FDA PDUFA Date Confirmed
The FDA's Priority Review and PDUFA goal date of July 17, 2026, for gedatolisib's New Drug Application (NDA) in HR+/HER2- PIK3CA wild-type ABC was reconfirmed.
Analysis · CELC · Industrial Applications And Services
This 8-K is highly important as it delivers a positive earnings surprise, with the company's adjusted Q1 loss beating analyst expectations. More critically, Celcuity announced a significant expansion of its pivotal Phase 3 VIKTORIA-2 trial to include a large, previously untapped patient population for first-line treatment of endocrine-sensitive breast cancer. This strategic move substantially increases the future market opportunity for gedatolisib. The company also confirmed its PDUFA date for another gedatolisib indication and is developing a more convenient subcutaneous formulation, reinforcing its long-term pipeline strategy.
At the time of this filing, CELC was trading at $129.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $9.51 to $151.02. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.